SBIR Phase I: Bioluminescence Resonance Energy Transfer Probes for Molecular Imaging

SBIR 第一阶段：用于分子成像的生物发光共振能量转移探针

• 批准号: 0839385
• 负责人: Daniel Sobek
• 金额: $ 10万
• 依托单位: Zymera Corporation
• 依托单位国家: 美国
• 项目类别: Standard Grant
• 财政年份: 2009
• 资助国家: 美国
• 起止时间: 2009-01-01 至 2009-06-30
• 项目状态: 已结题
• 来源: https://www.nsf.gov/awardsearch/showAward?AWD_ID=0839385&HistoricalAwards=false
• 关键词: SBIR; Phase; Bioluminescence; Resonance; Energy

This Small Business Innovation Research (SBIR) Phase I project will demonstrate the detection of an established target in cancer diagnosis and treatment using new targeted Bioluminescence Resonance Energy Transfer to Quantum Dots (BRET-QD) technology. BRET-QD offers substantial advantages over fluorescence or luminescence imaging by: (1), circumventing the need for external illumination while delivering comparable or better sensitivity; (2), providing compatibility with existing image capturing technology; (3), providing superior probe stability compared to radiolabel technology, enabling longitudinal studies; and (4), delivering greater in vivo penetration-depth than fluorescence-based probes. The project will demonstrate the direct detection of the HER2 cancer marker in breast cancer cell lines. Successful detection of HER2 in live cells from a breast cancer cell line will provide the proof-of-concept necessary for advancing to direct tumor and tissue imaging with BRET-QD probes in small animals.The broader impacts of this research are the development of a sensitive and convenient targeted imaging probe platform and its application to breast cancer detection. In order to understand the molecular mechanisms underlying diseases such as cancer, there is increasing interest in advancing from cell-based assays to in vivo imaging of disease states in small animal models. The targeted BRET-QD platform will provide a cost-effective, convenient and effective alternative to fluorescence and bioluminescence imaging probe technology. In addition to cancer applications, this platform will be applicable to virtually any investigation requiring sensitive detection of a known molecule that can be targeted via a biotinylated antibody or other biotinylated molecule.

这个小型企业创新研究(SBIR)第一阶段项目将展示使用新的定向生物发光共振能量转移到量子点(BRET-QD)技术检测癌症诊断和治疗中的既定目标。与荧光或发光成像相比，BRET-QD具有以下显著优势：(1)避免了对外部照明的需要，同时提供了相当或更好的灵敏度；(2)与现有图像捕获技术兼容；(3)与放射性标记技术相比，提供了更好的探头稳定性，从而能够进行纵向研究；以及(4)与基于荧光的探头相比，提供了更大的体内穿透深度。该项目将演示在乳腺癌细胞系中直接检测HER2癌症标记物。成功地从乳腺癌细胞系的活细胞中检测到HER2，将为进一步利用Bret-QD探针进行小动物的直接肿瘤和组织成像提供必要的概念验证。这项研究的更广泛的影响是开发一种敏感和方便的靶向成像探针平台，并将其应用于乳腺癌检测。为了了解癌症等疾病的分子机制，人们越来越有兴趣从基于细胞的分析发展到在小动物模型中对疾病状态的体内成像。靶向BRET-QD平台将为荧光和生物发光成像探头技术提供一种经济、方便和有效的替代技术。除了癌症应用，该平台将适用于几乎任何需要敏感检测已知分子的研究，这些已知分子可以通过生物素化抗体或其他生物素化分子作为靶标。